CCIA
STOK icon

Campbell & Co Investment Adviser’s Stoke Therapeutics STOK Stock Holding History

Campbell & Co Investment Adviser’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$490K Buy
15,049
+2,054
+16% +$67.4K 0.03% 761
2025
Q4 		$412K Sell
12,995
-17,423
-57% -$524K 0.02% 890
2025
Q3 		$715K Buy
+30,418
New +$521K 0.05% 568

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Campbell & Co Investment Adviser's STOK Position: Q1 2026 in Review

Campbell & Co Investment Adviser increased its Stoke Therapeutics (STOK) stake by 16% in Q1 2026, buying an estimated $67.4K and bringing the position to 15,049 shares worth $490K. The position accounts for 0.03% of the portfolio, ranked #761.

Campbell & Co Investment Adviser first reported a position in STOK in Q3 2025 and has held it in 3 quarters since. The position peaked at $715K in Q3 2025. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • Campbell & Co Investment Adviser held 15,049 shares of Stoke Therapeutics worth $490K as of Q1 2026.
  • Campbell & Co Investment Adviser bought 2,054 Stoke Therapeutics shares in Q1 2026, an estimated $67.4K.
  • Stoke Therapeutics made up 0.03% of Campbell & Co Investment Adviser's portfolio in Q1 2026, its #761 holding.
  • Campbell & Co Investment Adviser first reported a position in Stoke Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Campbell & Co Investment Adviser's Stoke Therapeutics position peaked at $715K in Q3 2025.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.